Related references
Note: Only part of the references are listed.Roles of ten-eleven translocation family proteins and their O-linked β-N-acetylglucosaminylated forms in cancer development
Hong-Jiao Li et al.
ONCOLOGY LETTERS (2021)
Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
Guoping Li et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2020)
Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
Xunwei Deng et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis
Wenxia Ma et al.
CANCER CELL INTERNATIONAL (2019)
Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells
Lubna Wasim et al.
CELLULAR ONCOLOGY (2018)
Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer
Fei Shan et al.
ONCOLOGY LETTERS (2018)
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
Siddhartha Devarakonda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers
Fermín Person et al.
TUMOR BIOLOGY (2017)
Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model
Hyo Joon Jang et al.
CANCER RESEARCH AND TREATMENT (2017)
ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy
M. El Baiomy et al.
BREAST (2017)
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance
Quan Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC
Hongxuan Zhou et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Muthu K. Kathiravan et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance
Shuai Wang et al.
MEDICAL SCIENCE MONITOR (2016)
EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in non-small cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy
Nannan Guo et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
J. Vansteenkiste et al.
ANNALS OF ONCOLOGY (2014)
Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis
Yongkang Yu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2014)
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)
C. Vulsteke et al.
ANNALS OF ONCOLOGY (2013)
Altered TUBB3 expression contributes to the epothilone response of mitotic cells
E. Narvi et al.
BRITISH JOURNAL OF CANCER (2013)
Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer
Gerold Bepler et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
F. P. O'Malley et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
L. Crino et al.
ANNALS OF ONCOLOGY (2010)
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
Charles A. Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients
A. V. Khrunin et al.
PHARMACOGENOMICS JOURNAL (2010)
Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
Koichi Azuma et al.
LUNG CANCER (2009)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
A new mathematical model for relative quantification in real-time RT-PCR
MW Pfaffl
NUCLEIC ACIDS RESEARCH (2001)
Share Paper
